Figure 1 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity

CLL-1 and CD33 expression in AML cell lines and patient blood samples. A, Surface expression of CLL-1 was analyzed in AML cell lines (EOL-1, HEL-92, HL-60, MOLM-13, THP-1, U937) and the CLL-1−CD33− lymphoma cell line (Raji) using flow cytometry. Cells were stained with a FITC-conjugated anti–CLL-1 antibody (green) or left unstained (gray) to assess specific binding. B, Surface expression of CD33 was evaluated in the same AML and lymphoma cell lines using flow cytometry. Cells were stained with a PE-conjugated CD33-specific antibody (green), and fluorescence intensity was compared with the unstained control (gray). C, Gating strategy of blast population side scatter (SSC) low and CD45 low. D, Expression of CD33 and CLL-1 in the primary AML peripheral blood samples. PE- conjugated CD33-specific antibody and PE-conjugated CLL-1–specific antibody (green) and unstained control (gray). Shown are overlays of histograms from one representative experiment, including the percentage of stained cells with a higher fluorescence intensity than the unstained control. Primary AML samples were used; n = 3. Cell line data were generated from three independent experiments.